RT Journal Article
SR Electronic
T1 A tale of two variants: Spread of SARS-CoV-2 variants Alpha in Geneva, Switzerland, and Beta in South Africa
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.10.21258468
DO 10.1101/2021.06.10.21258468
A1 Althaus, Christian L.
A1 Baggio, Stephanie
A1 Reichmuth, Martina L.
A1 Hodcroft, Emma B.
A1 Riou, Julien
A1 Neher, Richard A.
A1 Jacquerioz, Frédérique
A1 Spechbach, Hervé
A1 Salamun, Julien
A1 Vetter, Pauline
A1 Williamson, Carolyn
A1 Hsiao, Nei-yuan
A1 Preiser, Wolfgang
A1 Davies, Mary-Ann
A1 Lessells, Richard J.
A1 de Olivera, Tulio
A1 Kaiser, Laurent
A1 Eckerle, Isabella
YR 2021
UL http://medrxiv.org/content/early/2021/06/15/2021.06.10.21258468.abstract
AB Several SARS-CoV-2 variants of concern (VOC) are spreading rapidly in different regions of the world. The underlying mechanisms behind their transmission advantage remain unclear. We measured viral load in 950 individuals and found that infections with variant Alpha exhibit a higher viral load and longer viral shedding compared to non-VOC. We then used a transmission model to analyze the spread of variant Alpha in Geneva, Switzerland, and variant Beta in South Africa. We estimated that Alpha is either associated with a 37% (95% compatibility interval, CI: 25–63%) increase in transmissibility or a 51% (95% CI: 32–80%) increase of the infectious duration, or a combination of the two mechanisms. Assuming 50% immune evasion for Beta, we estimated a 23% (95% CI: 10–37%) increase in transmissibility or a 38% (95% CI: 15–78%) increase of the infectious duration for this variant. Beta is expected to outgrow Alpha in regions where the level of naturally acquired immunity from previously circulating variants exceeds 20% to 40%. Close monitoring of Alpha and Beta in regions with different levels of immunity will help to anticipate the global spread of these and future variants.Competing Interest StatementThe authors have declared no competing interest.Funding StatementCA received funding from the European Union's Horizon 2020 research and innovation programme - project EpiPose (No 101003688). CA, RN and EH received funding from the Swiss National Science Foundation (grant 196046). IE received funding from the Swiss National Foundation (grant 196644 and 196383) and the Private HUG Foundation by the Pictet Charitable Foundation. NGS-SA was supported by the Strategic Health Innovation Partnerships Unit of the South African Medical Research Council, with funds received from the South African Department of Science and Innovation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study (information on Ct value and days post onset of symptoms of SARS-CoV-2 positive individuals) was approved by the HUG institutional ethics board (no. 2020-00813).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and R code files are available on GitHub: https://github.com/calthaus/sarscov2-variants. https://github.com/calthaus/sarscov2-variants